Indivior Pharmaceuticals Inc (INDV)
NASDAQ • Healthcare
Last close at November 19, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Indivior Pharmaceuticals Inc keeps $38 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Indivior Pharmaceuticals topped consensus on both the top and bottom line in the third fiscal quarter of 2026, reported October 29, 2026, with revenue rising 13.4% year over year to about $356.0 million, driven by demand across its buprenorphine-based addiction-treatment portfolio. Adjusted EPS of $1.32 topped the $1.06 estimate (+24.5%), while revenue of $356.0 million topped the $329.4 million estimate (+8.1%). Profitability remained elevated, with gross profit of roughly $305.0 million translating to a gross margin of ~86% and operating income of about $181.0 million implying an operating margin near 51%. Net income climbed 226.2% to about $137.0 million, up from roughly $42.0 million a year ago, alongside the revenue increase from about $314.0 million in the prior-year quarter. The company generated operating cash flow of roughly $97.0 million. Consensus for the next period calls for EPS of $0.99 on revenue of $337.9 million.
About Indivior Pharmaceuticals Inc
Indivior Pharmaceuticals Inc is a healthcare holding company that researches, produces, and distributes buprenorphine-based prescription medications designed to treat opioid dependence. Listed on the NASDAQ as INDV, it generated $1.2 billion of revenue in FY2025 from a portfolio centered on addiction-treatment therapies.
Today's Snapshot
INDV closed 2.6% higher at 36.28, while its sector was flat.
Trading Volume
Above 10d avg 4.8M
4.8M
vs S&P 500 Today
Strong Outperformance
+6.06%
Updated: November 20, 2026 at 21:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$29.55 - $34.80Sell
- RSI (14)38.14Neutral
- Stochastic %K (14, 3, 3)30.00Neutral
- MACD Level (12, 26)-1.72Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.